H. Okuyama

发表

Salvage Line Chemotherapies in Metastatic Colorectal Cancer Patients

Y. Okita, A. Tsuji, H. Okuyama, 2018 .

Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment

K. Yamashita, N. Sugimoto, K. Ando, 2021, Frontiers in Oncology.

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study

K. Yamashita, E. Baba, N. Sugimoto, 2017, The oncologist.

E. Oki, K. Muro, K. Ando, 2021, International Journal of Clinical Oncology.

Prognostic Factors in Patients with Hepatocellular Carcinoma Refractory or Intolerant to Sorafenib

Hideaki Takahashi, A. Kuwahara, M. Ikeda, 2014, Oncology.

Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization

H. Ueno, Y. Arai, Hideaki Takahashi, 2014, Journal of Gastroenterology.

The impact of peritoneal lavage cytology in biliary tract cancer (KHBO1701): Kansai Hepato‐Biliary Oncology Group

Y. Takeda, H. Eguchi, A. Miyamoto, 2020, Cancer reports.

Reproducibility and prognostic significance of area of residual tumor (ART) in post-neoadjuvant resections of pancreatic ductal adenocarcinoma.

R. Kitazawa, M. Mino‐Kenudson, M. Kojima, 2021, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma

H. Ueno, Hideaki Takahashi, M. Ikeda, 2015, Journal of hepato-biliary-pancreatic sciences.

Successful Everolimus Treatment in a Patient with Advanced Pancreatic Neuroendocrine Tumor Who Developed Everolimus-Induced Interstitial Lung Disease on Two Occasions: A Case Report

M. Kojima, K. Goto, Hideaki Takahashi, 2013, Chemotherapy.

NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN)

R. Yamashita, I. Hyodo, K. Ando, 2022, Journal of Cancer Research and Clinical Oncology.

Risk Factor of the Hand/foot Skin Reaction Induced by Sorafenib in Patients with Advanced Hepatocellular Carcinoma

Hideaki Takahashi, M. Ikeda, S. Mitsunaga, 2013 .

Early Relapse of Unresectable Gallbladder Cancer after Discontinuation of Gemcitabine Monotherapy Administered for 5 Years in a Patient Who Had Complete Response to the Treatment

J. Furuse, M. Kojima, Hideaki Takahashi, 2013, Case Reports in Oncology.

A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol

T. Tsuji, N. Tatematsu, A. Inui, 2019, BMC Cancer.

Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study

R. Higuchi, K. Sugimachi, J. Furuse, 2022, AntiCancer Research.

Role of Predictive Value of the Modified Glasgow Prognostic Score for Later‐line Chemotherapy in Patients With Metastatic Colorectal Cancer

H. Ueno, E. Oki, K. Yamashita, 2018, Clinical colorectal cancer.

Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis

T. Nishiuchi, Yasuyuki Suzuki, K. Okano, 2021, Chemotherapy.

A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial)

T. Yamanaka, J. Furuse, M. Kojima, 2020, Neuroendocrinology.

C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer

H. Ueno, A. Ochiai, Hideaki Takahashi, 2016, Pancreas.

18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer

T. Masaki, H. Kobara, Yasuyuki Suzuki, 2018, Japanese journal of clinical oncology.

Transarterial (Chemo)Embolization for Liver Metastases in Patients with Neuroendocrine Tumors

H. Ueno, Y. Arai, Hideaki Takahashi, 2017, Oncology.

Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer

M. Ikeda, J. Odegaard, S. Itoh, 2023, British Journal of Cancer.

Current status of hepatocellular carcinoma in Japan.

Hideaki Takahashi, A. Kuwahara, M. Ikeda, 2013, Chinese clinical oncology.

Efficacy of Prophylactic Minocycline Treatment for Skin Toxicities Induced by Erlotinib Plus Gemcitabine in Patients with Advanced Pancreatic Cancer: A Retrospective Study

Hideaki Takahashi, M. Ikeda, T. Okusaka, 2015, American Journal of Clinical Dermatology.

Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities

Kazuhiro Yoshida, H. Shibata, M. Inoue, 2019, International Journal of Clinical Oncology.

Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment

H. Ueno, J. Furuse, Takamichi Kuwahara, 2023, Japanese journal of clinical oncology.

A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol

T. Tsuji, N. Tatematsu, A. Inui, 2019, BMC Cancer.

Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma

H. Ueno, Hideaki Takahashi, M. Ikeda, 2015, Journal of hepato-biliary-pancreatic sciences.

Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer.

K. Ohtsubo, M. Ueno, C. Morizane, 2024, British journal of cancer.